3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
2
Other solid neoplasm
1
Genitourinary
1
Gastrointestinal
1
CNS
1
Conditions
Wilms Tumor
1
Solid Tumors
1
Sarcoma, Ewing
1
Sarcoma, Clear Cell
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Retinoblastoma
1
Osteosarcoma
1
Neuroblastoma
1
Neoplasms, Germ Cell and Embryonal
1
Malignant Solid Tumors
1
Hepatoblastoma
1
Carcinoma, Renal Cell
1
Interventions
Granulocyte Colony-Stimulating Factor
3
Filgrastim
3
belinostat
2
Topotecan
2
Cyclophosphamide
2
Carboplatin
2
pembrolizumab
1
pegylated granulocyte colony-stimulating factor
1
entinostat
1
cixutumumab
1
alvocidib
1
alanosine
1
abemaciclib
1
Thrombopoietin
1
Thiotepa
1
Thalidomide
1
Sirolimus
1
Simvastatin
1
Quality of Life
1
Patient Reported Outcome Measures
1
Nivolumab
1
Molecular Diagnostic Techniques
1
LY2940680
1
Immunotherapy
1
Immunologic Techniques
1
Imatinib Mesylate
1
Ifosfamide
1
Fluorouracil
1
Fentanyl
1
Etoposide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Osteosarcoma
×
pegylated granulocyte colony-stimulating factor
×
Other solid neoplasm
×
Clear all
NCT02390843
2020-04-03
AflacST1402
Emory University
Phase 1
Completed
13 enrolled